GLYC Crescent Biopharma Inc.


$ 12.37 $ 0.19 (1.54 %)    

Friday, 17-Oct-2025 17:40:08 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 12.54
$ 12.21
$ 11.00 x 10
$ 12.53 x 50
$ 11.69 - $ 12.68
$ 9.81 - $ 63.00
115,482
na
na
$ 1.68
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 glycomimetics-merger-bound-crescent-appoints-joshua-brumm-as-ceo

Crescent also appointed Jonathan McNeill, president and chief operating officer; Ellie Im, M.D., chief medical officer; Rick Sc...

 cantor-fitzgerald-initiates-coverage-on-glycomimetics-with-overweight-rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on GlycoMimetics (NASDAQ:GLYC) with a Overweight rating.

 glycomimetics-and-crescent-amend-merger-agreement-crescent-to-own-9690-post-merger-200m-securities-purchase-reallocated-ownership-and-exchange-ratio-unchanged-18m-net-cash-at-closing

- SEC Filing

 glycomimetics-shares-are-soaring-tuesday-heres-why

GlycoMimetics, Inc. (NASDAQ:GLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent B...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION